Last reviewed · How we verify
NCT04268342: GRANDII
Gonorrhoea Resistance Assessment by Nucleic Acid Detection (GRANDII)
NA trial testing Resistance guided treatment for gonorrhoea infection in Drug Resistance, Microbial in 1,626 participants. Status unknown.
30 July 2023
Quick facts
| Lead sponsor | The University of Queensland |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 1,626 |
| Start date | 26 April 2022 |
| Primary completion | 30 July 2023 |
| Estimated completion | 30 July 2024 |
| Sites | 1 location across Australia |
Drugs / interventions tested
- Resistance guided treatment for gonorrhoea infection
Conditions studied
- Drug Resistance, Microbial — all drugs for Drug Resistance, Microbial →
- Antimicrobial Stewardship — all drugs for Antimicrobial Stewardship →
- Gonorrhea — all drugs for Gonorrhea →
Sponsor
The University of Queensland
Who can join
Eligibility, any sex, with Drug Resistance, Microbial or Antimicrobial Stewardship. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Three sexual health clinical services across Australia and their associated pathology testing laboratories are implementing a new management program for gonorrhoea infection. The services are implementing the use of gonorrhoea drug resistance testing as part of routine clinical and laboratory practice, where drug resistance test results are provided to clinicians quickly to guide choice of antibiotic therapy. Clinicians will identify gonorrhoea infection that is ciprofloxacin susceptible so that it can be treated with ciprofloxacin therapy, rather than ceftriaxone.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04268342
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Drug Resistance, Microbial
Currently open trials in the same condition.
- NCT06617260 — Longitudinal FolloW-up of Antimicrobial Resistance From Perinatal Acquisition (LWAPA): A SHARE Study ASSESSING AND PREVE · active not recruiting
Other The University of Queensland trials
Trials by the same sponsor.
- NCT06120673 — REmission in Membranous Nephropathy International Trial (REMIT) · Phase 3 · withdrawn
- NCT06642597 — STarting incrEmental Prescription of Peritoneal Dialysis · NA · recruiting
- NCT07114354 — Enhancing Utility of Neuropsychological Evaluation for Earlier and Effective Diagnosis of Dementia in Parkinson's Diseas · NA · not yet recruiting
- NCT06806709 — Reducing Blood Culture Contamination With the Use of a Needle-less Blood Draw Device (The PIVO Trial) · NA · recruiting
- NCT06882239 — SPINEPASS: SPINE Self-management Techniques for Persistent Headache After Concussion: Physical Therapy Targeting Autonom · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04268342 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The University of Queensland
- Last refreshed: 28 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04268342.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing